198 related articles for article (PubMed ID: 11325482)
1. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Dingemans AC; van Ark-Otte J; Span S; Scagliotti GV; van der Valk P; Postmus PE; Giaccone G
Lung Cancer; 2001 May; 32(2):117-28. PubMed ID: 11325482
[TBL] [Abstract][Full Text] [Related]
2. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
3. Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Rijavec M; Silar M; Triller N; Kern I; Cegovnik U; Košnik M; Korošec P
Pathol Oncol Res; 2011 Sep; 17(3):691-6. PubMed ID: 21455636
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
[TBL] [Abstract][Full Text] [Related]
5. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
6. Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Hirata S; Katoh O; Oguri T; Watanabe H; Yajin K
Jpn J Cancer Res; 2000 Jan; 91(1):84-90. PubMed ID: 10744048
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
8. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin.
Bader P; Fuchs J; Wenderoth M; von Schweinitz D; Niethammer D; Beck JF
Anticancer Res; 1998; 18(4C):3127-32. PubMed ID: 9713521
[TBL] [Abstract][Full Text] [Related]
12. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma].
Yu DQ; Yi YF
Ai Zheng; 2003 May; 22(5):496-9. PubMed ID: 12753710
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
15. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):778-84. PubMed ID: 11473729
[TBL] [Abstract][Full Text] [Related]
16. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
[TBL] [Abstract][Full Text] [Related]
17. MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.
Beck J; Niethammer D; Gekeler V
Leukemia; 1996 Jul; 10 Suppl 3():S39-S45. PubMed ID: 8656699
[TBL] [Abstract][Full Text] [Related]
18. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
[TBL] [Abstract][Full Text] [Related]
20. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
